Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis
Background and Aims We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC). Approach and Results Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity w...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2022-08, Vol.76 (2), p.303-316 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 316 |
---|---|
container_issue | 2 |
container_start_page | 303 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 76 |
creator | Roberts, Surain B. Hirschfield, Gideon M. Worobetz, Lawrence J. Vincent, Catherine Flemming, Jennifer A. Cheung, Angela Qumosani, Karim Swain, Mark Grbic, Dusanka Ko, Hin Hin Peltekian, Kevork Selzner, Nazia Abrahamyan, Lusine Aziz, Bishoi Lytvyak, Ellina Tirona, Kattleya Gulamhusein, Aliya F. Janssen, Harry L. A. Montano‐Loza, Aldo J. Mason, Andrew L. Hansen, Bettina E. |
description | Background and Aims
We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC).
Approach and Results
Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed‐effects regression. Health‐related quality of life was assessed using the Short Form 36, the PBC‐40 questionnaire, and the 5‐D Itch scale and analyzed using mixed‐effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event‐free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow‐up.
Conclusions
Indigenous Canadians with PBC present with advanced disease and have worse long‐term outcomes compared to White patients. |
doi_str_mv | 10.1002/hep.32426 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2634519992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2634519992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-f648ee2e186a42f76bd5f77fc9b6fd5a04019b0c664d0f661121897b90e56c733</originalsourceid><addsrcrecordid>eNp1kFFLwzAUhYMobk4f_AMS8EXBbjdJky6PMqYTBvqgzyFtb11G186m3di_t1unD4JPBy4fh3M_Qq4ZDBkAHy1wPRQ85OqE9JnkUSCEhFPSBx5BoJnQPXLh_RIAdMjH56QnJOegQPeJmdaLwiWu3j3Q1Hm0HqnHDVaHiy1S6ptq4zY2p66gE1vY1NmCrm3tsKg93bp6QdeVW9lqR2OXu30mizK3xaernb8kZ5nNPV4dc0A-nqbvk1kwf31-mTzOg0RIoYJMhWNEjmysbMizSMWpzKIoS3SsslRaCIHpGBKlwhQypRjjbKyjWANKlURCDMhd17uuyq8GfW1WzieYtzuwbLzhSoSSaa15i97-QZdlUxXtupbSe0dKspa676ikKr2vMDPHLw0Ds7duWuvmYL1lb46NTbzC9Jf80dwCow7Yuhx3_zeZ2fStq_wGS6-LPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2690094651</pqid></control><display><type>article</type><title>Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis</title><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Roberts, Surain B. ; Hirschfield, Gideon M. ; Worobetz, Lawrence J. ; Vincent, Catherine ; Flemming, Jennifer A. ; Cheung, Angela ; Qumosani, Karim ; Swain, Mark ; Grbic, Dusanka ; Ko, Hin Hin ; Peltekian, Kevork ; Selzner, Nazia ; Abrahamyan, Lusine ; Aziz, Bishoi ; Lytvyak, Ellina ; Tirona, Kattleya ; Gulamhusein, Aliya F. ; Janssen, Harry L. A. ; Montano‐Loza, Aldo J. ; Mason, Andrew L. ; Hansen, Bettina E.</creator><creatorcontrib>Roberts, Surain B. ; Hirschfield, Gideon M. ; Worobetz, Lawrence J. ; Vincent, Catherine ; Flemming, Jennifer A. ; Cheung, Angela ; Qumosani, Karim ; Swain, Mark ; Grbic, Dusanka ; Ko, Hin Hin ; Peltekian, Kevork ; Selzner, Nazia ; Abrahamyan, Lusine ; Aziz, Bishoi ; Lytvyak, Ellina ; Tirona, Kattleya ; Gulamhusein, Aliya F. ; Janssen, Harry L. A. ; Montano‐Loza, Aldo J. ; Mason, Andrew L. ; Hansen, Bettina E. ; Canadian Network for Autoimmune Liver Disease (CaNAL) ; the Canadian Network for Autoimmune Liver Disease (CaNAL)</creatorcontrib><description>Background and Aims
We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC).
Approach and Results
Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed‐effects regression. Health‐related quality of life was assessed using the Short Form 36, the PBC‐40 questionnaire, and the 5‐D Itch scale and analyzed using mixed‐effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event‐free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow‐up.
Conclusions
Indigenous Canadians with PBC present with advanced disease and have worse long‐term outcomes compared to White patients.</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.32426</identifier><identifier>PMID: 35220609</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Alkaline phosphatase ; Bilirubin ; Cholangitis ; Diagnosis ; Ethnicity ; Hepatology ; Liver ; Liver diseases ; Liver transplantation ; Minority & ethnic groups ; Patients ; Quality of life ; Survival ; Transplants & implants</subject><ispartof>Hepatology (Baltimore, Md.), 2022-08, Vol.76 (2), p.303-316</ispartof><rights>2022 American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-f648ee2e186a42f76bd5f77fc9b6fd5a04019b0c664d0f661121897b90e56c733</citedby><cites>FETCH-LOGICAL-c3536-f648ee2e186a42f76bd5f77fc9b6fd5a04019b0c664d0f661121897b90e56c733</cites><orcidid>0000-0002-6433-5956 ; 0000-0002-9435-2597 ; 0000-0002-9911-0925 ; 0000-0001-8792-2240</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.32426$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.32426$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35220609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberts, Surain B.</creatorcontrib><creatorcontrib>Hirschfield, Gideon M.</creatorcontrib><creatorcontrib>Worobetz, Lawrence J.</creatorcontrib><creatorcontrib>Vincent, Catherine</creatorcontrib><creatorcontrib>Flemming, Jennifer A.</creatorcontrib><creatorcontrib>Cheung, Angela</creatorcontrib><creatorcontrib>Qumosani, Karim</creatorcontrib><creatorcontrib>Swain, Mark</creatorcontrib><creatorcontrib>Grbic, Dusanka</creatorcontrib><creatorcontrib>Ko, Hin Hin</creatorcontrib><creatorcontrib>Peltekian, Kevork</creatorcontrib><creatorcontrib>Selzner, Nazia</creatorcontrib><creatorcontrib>Abrahamyan, Lusine</creatorcontrib><creatorcontrib>Aziz, Bishoi</creatorcontrib><creatorcontrib>Lytvyak, Ellina</creatorcontrib><creatorcontrib>Tirona, Kattleya</creatorcontrib><creatorcontrib>Gulamhusein, Aliya F.</creatorcontrib><creatorcontrib>Janssen, Harry L. A.</creatorcontrib><creatorcontrib>Montano‐Loza, Aldo J.</creatorcontrib><creatorcontrib>Mason, Andrew L.</creatorcontrib><creatorcontrib>Hansen, Bettina E.</creatorcontrib><creatorcontrib>Canadian Network for Autoimmune Liver Disease (CaNAL)</creatorcontrib><creatorcontrib>the Canadian Network for Autoimmune Liver Disease (CaNAL)</creatorcontrib><title>Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Background and Aims
We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC).
Approach and Results
Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed‐effects regression. Health‐related quality of life was assessed using the Short Form 36, the PBC‐40 questionnaire, and the 5‐D Itch scale and analyzed using mixed‐effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event‐free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow‐up.
Conclusions
Indigenous Canadians with PBC present with advanced disease and have worse long‐term outcomes compared to White patients.</description><subject>Alkaline phosphatase</subject><subject>Bilirubin</subject><subject>Cholangitis</subject><subject>Diagnosis</subject><subject>Ethnicity</subject><subject>Hepatology</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Minority & ethnic groups</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Survival</subject><subject>Transplants & implants</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kFFLwzAUhYMobk4f_AMS8EXBbjdJky6PMqYTBvqgzyFtb11G186m3di_t1unD4JPBy4fh3M_Qq4ZDBkAHy1wPRQ85OqE9JnkUSCEhFPSBx5BoJnQPXLh_RIAdMjH56QnJOegQPeJmdaLwiWu3j3Q1Hm0HqnHDVaHiy1S6ptq4zY2p66gE1vY1NmCrm3tsKg93bp6QdeVW9lqR2OXu30mizK3xaernb8kZ5nNPV4dc0A-nqbvk1kwf31-mTzOg0RIoYJMhWNEjmysbMizSMWpzKIoS3SsslRaCIHpGBKlwhQypRjjbKyjWANKlURCDMhd17uuyq8GfW1WzieYtzuwbLzhSoSSaa15i97-QZdlUxXtupbSe0dKspa676ikKr2vMDPHLw0Ds7duWuvmYL1lb46NTbzC9Jf80dwCow7Yuhx3_zeZ2fStq_wGS6-LPg</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Roberts, Surain B.</creator><creator>Hirschfield, Gideon M.</creator><creator>Worobetz, Lawrence J.</creator><creator>Vincent, Catherine</creator><creator>Flemming, Jennifer A.</creator><creator>Cheung, Angela</creator><creator>Qumosani, Karim</creator><creator>Swain, Mark</creator><creator>Grbic, Dusanka</creator><creator>Ko, Hin Hin</creator><creator>Peltekian, Kevork</creator><creator>Selzner, Nazia</creator><creator>Abrahamyan, Lusine</creator><creator>Aziz, Bishoi</creator><creator>Lytvyak, Ellina</creator><creator>Tirona, Kattleya</creator><creator>Gulamhusein, Aliya F.</creator><creator>Janssen, Harry L. A.</creator><creator>Montano‐Loza, Aldo J.</creator><creator>Mason, Andrew L.</creator><creator>Hansen, Bettina E.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6433-5956</orcidid><orcidid>https://orcid.org/0000-0002-9435-2597</orcidid><orcidid>https://orcid.org/0000-0002-9911-0925</orcidid><orcidid>https://orcid.org/0000-0001-8792-2240</orcidid></search><sort><creationdate>202208</creationdate><title>Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis</title><author>Roberts, Surain B. ; Hirschfield, Gideon M. ; Worobetz, Lawrence J. ; Vincent, Catherine ; Flemming, Jennifer A. ; Cheung, Angela ; Qumosani, Karim ; Swain, Mark ; Grbic, Dusanka ; Ko, Hin Hin ; Peltekian, Kevork ; Selzner, Nazia ; Abrahamyan, Lusine ; Aziz, Bishoi ; Lytvyak, Ellina ; Tirona, Kattleya ; Gulamhusein, Aliya F. ; Janssen, Harry L. A. ; Montano‐Loza, Aldo J. ; Mason, Andrew L. ; Hansen, Bettina E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-f648ee2e186a42f76bd5f77fc9b6fd5a04019b0c664d0f661121897b90e56c733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alkaline phosphatase</topic><topic>Bilirubin</topic><topic>Cholangitis</topic><topic>Diagnosis</topic><topic>Ethnicity</topic><topic>Hepatology</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Minority & ethnic groups</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Survival</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberts, Surain B.</creatorcontrib><creatorcontrib>Hirschfield, Gideon M.</creatorcontrib><creatorcontrib>Worobetz, Lawrence J.</creatorcontrib><creatorcontrib>Vincent, Catherine</creatorcontrib><creatorcontrib>Flemming, Jennifer A.</creatorcontrib><creatorcontrib>Cheung, Angela</creatorcontrib><creatorcontrib>Qumosani, Karim</creatorcontrib><creatorcontrib>Swain, Mark</creatorcontrib><creatorcontrib>Grbic, Dusanka</creatorcontrib><creatorcontrib>Ko, Hin Hin</creatorcontrib><creatorcontrib>Peltekian, Kevork</creatorcontrib><creatorcontrib>Selzner, Nazia</creatorcontrib><creatorcontrib>Abrahamyan, Lusine</creatorcontrib><creatorcontrib>Aziz, Bishoi</creatorcontrib><creatorcontrib>Lytvyak, Ellina</creatorcontrib><creatorcontrib>Tirona, Kattleya</creatorcontrib><creatorcontrib>Gulamhusein, Aliya F.</creatorcontrib><creatorcontrib>Janssen, Harry L. A.</creatorcontrib><creatorcontrib>Montano‐Loza, Aldo J.</creatorcontrib><creatorcontrib>Mason, Andrew L.</creatorcontrib><creatorcontrib>Hansen, Bettina E.</creatorcontrib><creatorcontrib>Canadian Network for Autoimmune Liver Disease (CaNAL)</creatorcontrib><creatorcontrib>the Canadian Network for Autoimmune Liver Disease (CaNAL)</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberts, Surain B.</au><au>Hirschfield, Gideon M.</au><au>Worobetz, Lawrence J.</au><au>Vincent, Catherine</au><au>Flemming, Jennifer A.</au><au>Cheung, Angela</au><au>Qumosani, Karim</au><au>Swain, Mark</au><au>Grbic, Dusanka</au><au>Ko, Hin Hin</au><au>Peltekian, Kevork</au><au>Selzner, Nazia</au><au>Abrahamyan, Lusine</au><au>Aziz, Bishoi</au><au>Lytvyak, Ellina</au><au>Tirona, Kattleya</au><au>Gulamhusein, Aliya F.</au><au>Janssen, Harry L. A.</au><au>Montano‐Loza, Aldo J.</au><au>Mason, Andrew L.</au><au>Hansen, Bettina E.</au><aucorp>Canadian Network for Autoimmune Liver Disease (CaNAL)</aucorp><aucorp>the Canadian Network for Autoimmune Liver Disease (CaNAL)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2022-08</date><risdate>2022</risdate><volume>76</volume><issue>2</issue><spage>303</spage><epage>316</epage><pages>303-316</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><abstract>Background and Aims
We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC).
Approach and Results
Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples were grouped. Clinical events were defined as liver decompensation, HCC, liver transplantation, or death. Clinical event–free and liver transplantation–free survival were analyzed using Cox regression. Trajectories of serum liver function tests were assessed over time using mixed‐effects regression. Health‐related quality of life was assessed using the Short Form 36, the PBC‐40 questionnaire, and the 5‐D Itch scale and analyzed using mixed‐effects regression. The cohort included 1538 patients with PBC from six sites and was comprised of 82% White, 4.7% Indigenous, 5.5% East Asian, 2.6% South Asian, and 5.1% miscellaneous ethnicities. Indigenous patients were the only ethnic group with impaired liver transplant–free and event‐free survival compared to White patients (HR, 3.66; 95% CI, 2.23–6.01; HR, 3.09; 95% CI, 1.94–4.92). Indigenous patients were more likely to have a clinical event before diagnosis (10%) than all other ethnic groups despite similar age at diagnosis. Indigenous patients presented with higher alkaline phosphatase, total bilirubin, and GLOBE scores than White patients; and these relative elevations persisted during follow‐up.
Conclusions
Indigenous Canadians with PBC present with advanced disease and have worse long‐term outcomes compared to White patients.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35220609</pmid><doi>10.1002/hep.32426</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6433-5956</orcidid><orcidid>https://orcid.org/0000-0002-9435-2597</orcidid><orcidid>https://orcid.org/0000-0002-9911-0925</orcidid><orcidid>https://orcid.org/0000-0001-8792-2240</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2022-08, Vol.76 (2), p.303-316 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_proquest_miscellaneous_2634519992 |
source | Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
subjects | Alkaline phosphatase Bilirubin Cholangitis Diagnosis Ethnicity Hepatology Liver Liver diseases Liver transplantation Minority & ethnic groups Patients Quality of life Survival Transplants & implants |
title | Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T13%3A35%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ethnicity,%20disease%20severity,%20and%20survival%20in%20Canadian%20patients%20with%20primary%20biliary%20cholangitis&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Roberts,%20Surain%20B.&rft.aucorp=Canadian%20Network%20for%20Autoimmune%20Liver%20Disease%20(CaNAL)&rft.date=2022-08&rft.volume=76&rft.issue=2&rft.spage=303&rft.epage=316&rft.pages=303-316&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.32426&rft_dat=%3Cproquest_cross%3E2634519992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2690094651&rft_id=info:pmid/35220609&rfr_iscdi=true |